Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vericel Corp VCEL

Healthcare Biotechnology
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic... see more

Recent & Breaking News (NDAQ:VCEL)

Free Research Reports on ASTM, FRO, LCC and LNDC Issued by the Bedford Report

Marketwired March 28, 2013

Aastrom Biosciences Announces Strategic Change in Research and Development Programs to Focus on Dilated Cardiomyopathy and Other Rare Disease Indications

Globe Newswire March 27, 2013

Aastrom Biosciences Reports Fourth-Quarter and Year-End 2012 Financial Results

Troy Schwensen March 18, 2013

Aastrom to Host Fourth Quarter 2012 Investor Call on March 18, 2013

Troy Schwensen March 12, 2013

Aastrom Board of Directors Names Dominick C. Colangelo President and Chief Executive Officer

Troy Schwensen March 6, 2013

U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous

Marketwired February 21, 2013

Biotech Industry Expected to Experience More M&A Activity in 2013

Marketwired January 17, 2013